Antimicrobial Agents and ChemotherapyMicrobiologyPeer-reviewed journal article
An arylsulphonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis
R. H. Allen, Lauren Ames, Vanessa Pietrowski BaldiniD, Arielle Butts, Kenneth J. Henry, Greg Durst, Diana Quach, Joseph SugieiD, Joe PoglianoiD, Tanya ParishiD
Abstract
We investigated the mechanism of action of an arylsulphonamide with whole cell activity against Mycobacterium tuberculosis. We newly synthesized the molecule and confirmed it had activity against both extracellular and intracellular bacilli. The molecule had some activity against HepG2 cells but maintained some selectivity. Bacterial cytological profiling suggested that mechanism of action was via disruption of cell wall synthesis, with similarities to an inhibitor of the mycolic acid exporter MmpL3. The compound induced expression from the IniB promoter and caused a boost in ATP production but did not induce reactive oxygen species. A mutation in MmpL3 (S591I) led to low-level resistance. Taken together these data confirm the molecule targets cell wall biosynthesis with MmpL3 as the most probable target.
- organism: bacteria (other)
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 6
- FWCI
- 1.85
- Field percentile
- top 15%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis
Vanessa Pietrowski Baldin, Christopher L. Harding, … Tanya Parish·Antimicrobial Agents and ChemotherapyPeer-reviewed·Sep 22, 2025
- Inoculum-dependent bactericidal activity of a Mycobacterium tuberculosis MmpL3 inhibitor
B. Berube, A. Deshpande, … T. Parish·bioRxiv·Feb 22, 2023
- Common biological features of Mycobacterium tuberculosis MmpL3 inhibitors
Lauren Ames, R. H. Allen, … Tanya Parish·bioRxiv·Mar 31, 2025
- Identification of new MmpL3 inhibitors by untargeted and targeted mutant screens defines MmpL3 domains with differential resistance
J. T. Williams, E. R. Haiderer, … R. B. Abramovitch·bioRxiv·Feb 28, 2019
- Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly.
A. B. Lanne, Y. Cui, … L. J. Alderwick·bioRxiv·Sep 3, 2020
- Endolysin B: A new archetype in M. tuberculosis treatment
A. Griego, B. Antinori, … L. Rizzello·bioRxiv·Dec 5, 2023